Projects

MVDr. Juraj Kopáček, DrSc.
Director

International

Current
  • Alliance4Life Bridging the Research and Innovation Gap in Life Sciences
    Program: Horizon Europe
    Duration: 1. 3. 2024 – 29. 2. 2028
Finished
  • Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe
    Program: Horizon 2020
    Duration: 1. 5. 2021 – 30. 4. 2024
  • Biomarkers for Early Detection and Therapy of Adrenal Gland Tumors: Molecular Pathogenesis and Clinical Correlates
    Program: SRDA
    Duration: 1. 1. 2009 – 31. 12. 2014
  • Analysis of the constituents of the PAVIVAC vaccine
    Program: Bilateral - other
    Duration: 1. 1. 2009 – 31. 12. 2009

National

Current
  • Study of inverse relationship between carbonic anhydrases CA IX and CA IV and its significance for tumor phenotype
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
Finished
  • Cell-in-cell phenomena as microevolutionary processes in cancer progression: a role for hypoxia-induced carbonic anhydrase IX
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Strengthening of research, development and innovation capacities of translational biomedical research of human diseases
    Program:
    Duration: 1. 1. 2020 – 30. 6. 2023
  • Improvement of the biotechnological research potential of the Biomedical Research Center of the Slovak Academy of Sciences to combat the pandemic COVID-19 in synergy with the European Virus Archive of Global Importance supported by the H2020 program
    Program:
    Duration: 1. 4. 2020 – 30. 6. 2023
  • Regulation of pyruvate dehydrogenase kinase 1 activity in the control of glycolytic metabolism in hypoxic tumors
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Intelligent monitoring of wastewater in order to create a system of early warning of the population of the Slovak Republic against the spread of COVID-19
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Large-capacity cleaning of airborne pathogens
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Activity Assay of Transfer Factor, Immunostimulatory Drug from Leukocytes Extract And Its Preparation Standardization
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Drug repurposing as a novel approach to therapy of colorectal carcinoma: molecular mechanisms and potential applications
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Molecular pathways influenced by CA IX in hypoxic cancer cell lines
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 3. 2014 – 31. 12. 2015
  • Regulation of carbonic anhydrase IX release and biological role of shed ectodomain in tumor cell-cell interactions
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 10. 2011 – 31. 10. 2015
  • Centre for Innovative Research of Antitumor and Antiviral Strategies
    Program: EU Structural Funds Research & Development
    Duration: 1. 5. 2011 – 31. 8. 2015
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 7. 2012 – 30. 6. 2015
  • -
    Program:
    Duration: 1. 6. 2011 – 31. 12. 2014
  • Center of excellence for the study of metabolic aspects of development, diagnostics and treatment of cancer diseases
    Program:
    Duration: 1. 7. 2011 – 31. 12. 2014
  • Identification of the cellular proteins affected by persistent infection with lymphocytic choriomeningitis virus
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Proteomic analysis of cells with modulated expression of calcium-binding protein S100P
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Identification of the molecular pathways driven by hypoxia-induced carbonic anhydrase IX in tumor cells
    Program: SRDA
    Duration: 1. 5. 2011 – 31. 10. 2014
  • Industrial Research in Clinical Diagnostics of Infectious Pathogens
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2013
  • Identification of selected bioactive molecules secreted in tick saliva
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Centre of Excellence for Translational Research in Molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2012
  • Improvement of Centre of Excelence for the Use of Informational Biomacromolecules in Prevention of Diseases and for Improvement of the Quality of Life
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 30. 4. 2012
  • Study of hypoxia inducible carbonic anhydrase IX function in the tumor phenotype utilizing inducible RNA interference
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Center of Excelence for Translational Research in Molecular Medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2009 – 31. 5. 2011
  • Prevalence and medical significance of lymphocytic choriomeningitis virus in Slovak population
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Molecular-biological characterization of selected tick’s salivary proteins as a potential antigens for development of anti-tick vaccines
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Interplay between the molecular mechanisms of the responses to hypoxia and xenobiotics: impact on CA9 gene expression and tumor phenotype
    Program: SRDA
    Duration: 1. 3. 2006 – 30. 6. 2009
  • Epithelial-mesenchymal transition in the model of breast carcinoma stem cells in vitro
    Program: SRDA
    Duration: 1. 3. 2006 – 1. 3. 2009
  • Mutual relationship between hypoxia and oncogenic DNA viruses and its effects on the expression of viral and cellular genes
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees